Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free CSBR Stock Alerts

Champions Oncology (CSBR) Financials

Champions Oncology logo
$6.13 +0.29 (+4.97%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$6.13 0.00 (0.00%)
As of 07/17/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Champions Oncology

Annual Income Statements for Champions Oncology

This table shows Champions Oncology's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Net Income / (Loss) Attributable to Common Shareholders		 0.00 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70
Consolidated Net Income / (Loss)		 0.00 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70
Net Income / (Loss) Continuing Operations		 0.00 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70
Total Pre-Tax Income 		0.00 -10 -6.87 -1.44 0.23 -1.96 0.44 0.58 -5.27 -7.31 4.63
Total Operating Income		 0.00 -10 -6.81 -1.35 0.27 -1.92 0.37 0.61 -5.26 -7.36 4.55
Total Gross Profit		 0.00 11 15 20 27 15 20 25 24 21 29
Total Revenue		 0.00 11 15 20 27 32 41 49 54 50 57
Operating Revenue		 - 11 15 20 27 32 41 49 54 50 57
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 17 21 24 30 29 28
Operating Cost of Revenue		 - - - - - 17 21 24 30 29 28
Total Operating Expenses		 0.00 21 22 22 27 17 19 25 30 28 24
Selling, General & Admin Expense		 - 5.17 4.96 4.07 4.68 6.61 6.51 9.12 10 11 9.34
Marketing Expense		 - 3.45 3.26 2.57 3.06 4.24 5.52 6.38 7.00 7.06 7.55
Research & Development Expense		 - 4.19 4.29 4.40 4.80 5.85 7.20 9.37 12 9.54 6.83
Other Special Charges / (Income)		 - - - - - - - - 0.00 0.44 0.29
Total Other Income / (Expense), net		 0.00 -0.04 -0.06 -0.09 -0.04 -0.04 0.07 -0.02 -0.01 0.05 0.07
Other Income / (Expense), net		 - -0.04 -0.06 -0.09 -0.04 -0.04 0.07 -0.02 -0.01 0.05 0.07
Income Tax Expense		 - 0.09 0.02 0.03 0.10 0.13 0.08 0.04 0.07 -0.03 -0.08
Basic Earnings per Share		 ($2.20) ($1.20) ($0.64) ($0.13) $0.01 ($0.18) $0.03 $0.04 ($0.39) ($0.54) $0.34
Weighted Average Basic Shares Outstanding		 5.99M 8.70M 10.68M 10.99M 11.34M 11.84M 13.14M 13.20M 13.54M 13.55M 13.66M
Diluted Earnings per Share		 ($2.20) ($1.20) ($0.64) ($0.13) $0.01 ($0.18) $0.02 $0.04 ($0.39) ($0.54) $0.33
Weighted Average Diluted Shares Outstanding		 6.42M 8.70M 10.68M 10.99M 14.10M 11.84M 14.57M 14.16M 13.54M 13.55M 14.27M
Weighted Average Basic & Diluted Shares Outstanding		 71.82M 8.70M 10.68M 10.99M 11.62M 12.73T 13.42M 13.52M 13.46M 13.59M 13.78M

Quarterly Income Statements for Champions Oncology

This table shows Champions Oncology's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 -2.57 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.44 0.27 -0.28
Consolidated Net Income / (Loss)		 -2.57 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28
Net Income / (Loss) Continuing Operations		 -2.57 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28
Total Pre-Tax Income 		-2.54 -2.06 -2.52 -0.19 1.33 0.74 4.52 -1.97 -0.45 0.26 -0.24
Total Operating Income		 -2.55 -1.96 -2.58 -0.27 1.33 0.73 4.50 -2.01 -0.53 0.19 -0.28
Total Gross Profit		 4.88 4.96 4.17 6.75 6.99 6.06 10 5.08 6.00 7.77 7.73
Total Revenue		 13 12 12 14 14 13 17 12 14 15 17
Operating Revenue		 13 12 12 14 14 13 17 12 14 15 17
Total Cost of Revenue		 7.68 6.62 7.85 7.25 7.07 7.43 6.62 7.27 8.00 7.26 8.83
Operating Cost of Revenue		 7.68 6.62 7.85 7.25 7.07 7.43 6.62 7.27 8.00 7.26 8.83
Total Operating Expenses		 7.43 6.91 6.75 7.02 5.66 5.33 5.92 7.09 6.53 7.59 8.00
Selling, General & Admin Expense		 2.94 2.60 2.76 2.76 2.53 1.89 2.40 2.53 2.57 2.97 2.98
Marketing Expense		 1.70 1.80 1.80 1.78 1.68 1.75 1.81 2.31 1.86 2.00 2.67
Research & Development Expense		 2.79 2.52 2.19 2.05 1.45 1.69 1.72 1.96 2.08 2.62 2.27
Other Special Charges / (Income)		 - - - - 0.00 0.00 0.00 - 0.02 0.00 0.09
Total Other Income / (Expense), net		 0.01 -0.11 0.06 0.08 0.01 0.01 0.02 0.04 0.08 0.07 0.04
Other Income / (Expense), net		 0.01 -0.11 0.06 0.08 0.01 0.01 0.02 0.04 0.08 0.07 0.04
Income Tax Expense		 0.03 0.01 0.01 -0.08 0.02 0.01 0.02 -0.13 0.01 0.02 0.04
Basic Earnings per Share		 ($0.19) ($0.15) ($0.19) ($0.01) $0.10 $0.05 $0.33 ($0.14) ($0.03) $0.02 ($0.02)
Weighted Average Basic Shares Outstanding		 13.51M 13.50M 13.59M 13.55M 13.59M 13.59M 13.70M 13.66M 13.79M 13.79M 13.89M
Diluted Earnings per Share		 ($0.19) ($0.15) ($0.19) ($0.01) $0.09 $0.05 $0.31 ($0.12) ($0.03) $0.02 ($0.02)
Weighted Average Diluted Shares Outstanding		 13.51M 13.50M 13.59M 13.55M 14.04M 14.02M 14.36M 14.27M 13.79M 14.46M 13.89M
Weighted Average Basic & Diluted Shares Outstanding		 13.48M 13.59M 13.59M 13.59M 13.59M 13.82M 13.83M 13.78M 13.79M 13.89M 13.89M

Annual Cash Flow Statements for Champions Oncology

This table details how cash moves in and out of Champions Oncology's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Net Change in Cash & Equivalents		 3.47 -6.77 0.71 -2.44 2.23 5.11 -3.66 4.32 1.11 -7.50 7.17
Net Cash From Operating Activities		 -9.63 -6.41 -2.84 -1.23 1.86 2.91 -1.68 6.50 3.97 -6.14 7.39
Net Cash From Continuing Operating Activities		 -9.63 -6.42 -2.84 -1.23 1.86 2.91 -1.68 6.50 3.97 -6.14 7.39
Net Income / (Loss) Continuing Operations		 -13 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70
Consolidated Net Income / (Loss)		 -13 -10 -6.88 -1.48 0.13 -2.09 0.36 0.55 -5.34 -7.28 4.70
Depreciation Expense		 0.21 0.16 0.17 0.36 0.61 0.83 1.18 1.63 2.25 1.87 1.64
Non-Cash Adjustments To Reconcile Net Income		 2.77 2.67 2.73 0.99 0.71 1.16 0.73 1.99 1.91 1.93 1.85
Changes in Operating Assets and Liabilities, net		 0.52 1.20 1.15 -1.10 0.42 3.01 -3.96 2.34 5.15 -2.65 -0.80
Net Cash From Investing Activities		 -0.11 -0.32 -0.77 -1.23 -0.83 -2.22 -3.17 -2.38 -2.87 -0.84 -0.39
Net Cash From Continuing Investing Activities		 -0.11 -0.32 -0.77 -1.23 -0.83 -2.22 -3.17 -2.38 -2.87 -0.84 -0.39
Purchase of Property, Plant & Equipment		 -0.12 -0.32 -0.77 -1.23 -0.83 -2.22 -3.28 -2.38 -2.87 -0.84 -0.39
Net Cash From Financing Activities		 13 -0.04 4.32 0.01 1.20 4.42 1.20 0.21 0.01 -0.53 0.17
Net Cash From Continuing Financing Activities		 13 -0.04 4.32 0.01 1.20 4.42 1.20 0.21 0.01 -0.53 0.17
Repurchase of Common Equity		 0.00 -0.02 - - - - - 0.00 -0.07 -0.63 0.00
Other Financing Activities, net		 0.00 - 0.00 0.04 1.47 4.42 1.20 0.21 0.09 0.11 0.17

Quarterly Cash Flow Statements for Champions Oncology

This table details how cash moves in and out of Champions Oncology's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026
Net Change in Cash & Equivalents		 -5.25 0.64 -1.05 -1.85 0.27 -0.14 0.45 6.58 0.54 -1.81 -1.39
Net Cash From Operating Activities		 -3.99 0.59 -0.92 -1.82 0.31 -0.28 0.49 6.87 0.60 -1.74 -1.34
Net Cash From Continuing Operating Activities		 -3.99 0.59 -0.92 -1.82 0.31 -0.28 0.49 6.87 0.60 -1.74 -1.34
Net Income / (Loss) Continuing Operations		 -2.57 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28
Consolidated Net Income / (Loss)		 -2.57 -2.07 -2.53 -0.11 1.31 0.73 4.50 -1.84 -0.47 0.24 -0.28
Depreciation Expense		 0.45 0.48 0.48 0.46 0.45 0.40 0.40 0.39 0.36 0.36 0.34
Non-Cash Adjustments To Reconcile Net Income		 0.56 0.71 0.76 -0.11 0.48 -0.56 1.17 1.76 0.15 0.20 0.43
Changes in Operating Assets and Liabilities, net		 -2.43 1.46 0.38 -2.06 -1.93 -0.85 -5.57 6.55 0.56 -2.53 -1.83
Net Cash From Investing Activities		 -0.67 -0.08 -0.09 0.00 0.00 -0.09 -0.04 -0.25 -0.05 -0.24 -0.01
Net Cash From Continuing Investing Activities		 -0.67 -0.08 -0.09 0.00 0.00 -0.09 -0.04 -0.25 -0.05 -0.24 -0.01
Purchase of Property, Plant & Equipment		 -0.67 -0.08 -0.09 0.00 0.00 -0.09 -0.04 -0.25 -0.05 -0.24 -0.04
Net Cash From Financing Activities		 -0.59 0.13 -0.03 -0.04 -0.04 0.24 - -0.03 -0.01 0.17 -0.04
Net Cash From Continuing Financing Activities		 -0.59 0.13 -0.03 -0.04 -0.04 0.24 - -0.03 -0.01 0.17 -0.04
Other Financing Activities, net		 0.01 0.17 -0.03 -0.04 -0.04 0.24 - -0.03 -0.01 0.17 -0.04

Annual Balance Sheets for Champions Oncology

This table presents Champions Oncology's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
Total Assets		 12 5.78 8.01 8.08 11 21 28 35 34 26 32
Total Current Assets		 11 4.34 5.87 5.06 7.92 13 13 20 19 14 22
Cash & Equivalents		 9.36 2.59 3.30 - 3.24 8.34 4.69 9.01 10 2.62 9.79
Accounts Receivable		 1.06 1.31 2.27 3.92 4.38 4.77 6.99 9.51 8.01 9.53 11
Prepaid Expenses		 0.35 0.44 0.30 0.29 0.31 0.39 0.96 1.14 1.33 1.50 1.37
Plant, Property, & Equipment, net		 0.45 0.62 1.22 2.08 2.55 3.99 0.00 7.13 7.19 5.72 4.38
Total Noncurrent Assets		 0.83 0.82 0.93 0.94 0.80 3.26 15 8.58 7.67 6.77 5.61
Goodwill		 0.67 0.67 0.67 0.67 0.67 0.34 0.34 0.34 0.34 0.34 0.34
Other Noncurrent Operating Assets		 - 0.00 0.11 0.12 0.13 2.93 15 8.25 7.33 6.44 5.28
Total Liabilities & Shareholders' Equity		 12 5.78 8.01 8.08 11 21 28 35 34 26 32
Total Liabilities		 3.99 5.54 7.61 8.08 9.03 16 20 26 30 28 29
Total Current Liabilities		 3.80 5.31 7.45 7.45 8.03 12 11 17 22 22 24
Accounts Payable		 1.41 1.90 1.85 2.15 2.81 3.14 1.89 2.87 5.33 5.80 4.25
Accrued Expenses		 0.37 0.27 0.69 0.57 1.18 2.72 2.23 2.41 2.27 2.16 2.56
Current Deferred Revenue		 2.01 3.14 4.91 4.70 4.02 5.82 6.26 11 13 12 15
Other Current Liabilities		 - - - - 0.00 0.63 0.82 1.13 1.35 1.49 1.61
Total Noncurrent Liabilities		 0.19 0.23 0.16 0.62 1.00 3.35 8.96 8.80 7.94 6.49 4.72
Other Noncurrent Operating Liabilities		 0.19 0.23 0.16 0.15 0.15 3.35 8.96 8.80 7.94 6.49 4.72
Total Equity & Noncontrolling Interests		 8.06 0.24 0.40 0.00 2.24 5.10 7.43 9.10 4.64 -1.90 3.77
Total Preferred & Common Equity		 8.06 0.24 0.40 0.00 2.24 5.10 7.43 9.10 4.64 -1.90 3.77
Total Common Equity		 8.06 0.24 0.40 0.00 2.24 5.10 7.43 9.10 4.64 -1.90 3.77
Common Stock		 61 64 71 72 73 78 80 81 82 83 84
Retained Earnings		 -52 -62 -69 -71 -71 -73 -73 -72 -77 -85 -80
Treasury Stock		 -1.25 -1.25 -1.25 -1.25 - - - 0.00 -0.07 -0.71 -0.71
Noncontrolling Interest		 - - - - - - - - - - 0.00

Quarterly Balance Sheets for Champions Oncology

This table presents Champions Oncology's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 7/31/2024 10/31/2024 1/31/2025 7/31/2025 10/31/2025 1/31/2026
Total Assets		 30 28 27 25 25 31 31 30 28
Total Current Assets		 15 14 13 13 14 20 21 21 20
Cash & Equivalents		 4.87 5.51 4.47 2.89 2.75 3.20 10 8.52 7.13
Accounts Receivable		 8.95 7.72 7.90 9.03 10 16 9.47 12 12
Prepaid Expenses		 1.11 0.78 0.84 1.25 0.86 0.71 1.22 1.28 0.99
Plant, Property, & Equipment, net		 7.37 6.94 6.53 5.27 4.97 5.04 4.23 3.95 3.71
Total Noncurrent Assets		 7.61 7.34 7.06 6.48 6.19 5.89 5.30 4.88 4.56
Goodwill		 0.34 0.34 0.34 0.34 0.34 0.34 0.34 0.34 0.34
Other Noncurrent Operating Assets		 7.28 7.00 6.72 6.15 5.85 5.56 4.97 4.54 4.22
Total Liabilities & Shareholders' Equity		 30 28 27 25 25 31 31 30 28
Total Liabilities		 28 28 29 25 25 25 27 26 24
Total Current Liabilities		 20 21 22 19 19 20 23 22 21
Accounts Payable		 5.76 4.54 4.76 5.24 4.85 5.09 4.85 5.99 5.73
Accrued Expenses		 2.09 2.02 2.43 2.10 2.24 2.27 1.80 2.19 3.35
Current Deferred Revenue		 11 13 13 10 10 11 14 12 10.00
Other Current Liabilities		 1.39 1.42 1.31 1.52 1.55 1.59 1.62 1.62 1.61
Total Noncurrent Liabilities		 7.62 7.25 6.88 6.10 5.70 5.29 4.31 3.79 3.39
Other Noncurrent Operating Liabilities		 7.62 7.25 6.88 6.10 5.70 5.29 4.31 3.79 3.39
Total Equity & Noncontrolling Interests		 1.90 0.09 -2.06 -0.33 0.68 5.47 3.54 4.23 4.38
Total Preferred & Common Equity		 1.90 0.09 -2.06 -0.33 0.68 5.47 3.51 4.17 4.28
Total Common Equity		 1.90 0.09 -2.06 -0.33 0.68 5.47 3.51 4.17 4.28
Common Stock		 82 83 83 84 84 84 85 85 85
Retained Earnings		 -80 -82 -84 -83 -83 -78 -80 -80 -80
Treasury Stock		 -0.68 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71 -0.71
Noncontrolling Interest		 - - - - - - 0.03 0.06 0.10

Annual Metrics And Ratios for Champions Oncology

This table displays calculated financial ratios and metrics derived from Champions Oncology's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 4/30/2015 4/30/2016 4/30/2017 4/30/2018 4/30/2019 4/30/2020 4/30/2021 4/30/2022 4/30/2023 4/30/2024 4/30/2025
DEI Shares Outstanding		 104,026,506.00 8,702,237.00 10,978,352.00 11,000,847.00 11,615,272.00 11,887,649.00 13,390,172.00 13,522,441.00 13,558,650.00 13,593,767.00 13,826,904.00
DEI Adjusted Shares Outstanding		 104,026,506.00 8,702,237.00 10,978,352.00 11,000,847.00 11,615,272.00 11,887,649.00 13,390,172.00 13,522,441.00 13,558,650.00 13,593,767.00 13,826,904.00
DEI Earnings Per Adjusted Shares Outstanding		 0.00 -1.20 -0.63 -0.13 0.01 -0.18 0.03 0.04 -0.39 -0.54 0.34
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -100.00% 0.00% 37.82% 31.34% 33.72% 18.68% 27.76% 19.66% 9.69% -6.90% 13.54%
EBITDA Growth		 102.98% -4,865.42% 34.33% 83.83% 177.29% -235.96% 242.44% 36.34% -236.70% -80.11% 215.16%
EBIT Growth		 100.00% 0.00% 33.70% 78.98% 116.01% -949.78% 122.26% 33.41% -1,003.43% -38.75% 163.30%
NOPAT Growth		 100.00% 0.00% 34.00% 80.11% 115.79% -998.80% 122.55% 88.19% -744.84% -39.95% 189.86%
Net Income Growth		 100.00% 0.00% 34.10% 78.56% 108.67% -1,735.16% 117.30% 51.38% -1,073.54% -36.38% 164.61%
EPS Growth		 -1,900.00% 45.45% 46.67% 79.69% 107.69% -1,900.00% 111.11% 100.00% -1,075.00% -38.46% 161.11%
Operating Cash Flow Growth		 -180.51% 33.46% 55.68% 56.83% 251.88% 56.02% -157.87% 486.50% -38.86% -254.51% 220.35%
Free Cash Flow Firm Growth		 61.17% -342.43% 31.80% 7.81% 126.45% -11.02% -720.65% 156.73% -41.30% -422.98% 200.14%
Invested Capital Growth		 48.90% -70.91% -21.95% 96.58% -845.19% -229.91% 184.52% -96.75% -6,259.55% 17.53% -33.00%
Revenue Q/Q Growth		 -100.00% 310.80% 6.07% 6.32% 11.52% 3.31% 4.63% 4.94% 0.36% 1.89% -2.81%
EBITDA Q/Q Growth		 101.87% -417.40% 2.09% 63.26% 174.43% -259.61% 1,137.40% 33.94% -259.22% 29.02% -22.67%
EBIT Q/Q Growth		 100.00% -439.36% 2.05% 55.49% 198.30% -4,933.33% 143.88% 102.43% -71.45% 24.33% -27.72%
NOPAT Q/Q Growth		 100.00% -336.68% 2.31% 56.99% 200.82% -31,916.67% 142.55% 176.87% -72.55% 23.41% -26.73%
Net Income Q/Q Growth		 100.00% -765.95% 2.10% 54.84% 150.79% -1,069.27% 132.01% 150.23% -71.10% 25.21% -26.86%
EPS Q/Q Growth		 -13.99% 0.00% 13.51% 53.57% 150.00% -500.00% 122.22% 0.00% -77.27% 25.00% -25.00%
Operating Cash Flow Q/Q Growth		 -28.45% 18.48% 25.13% -46.48% 15.01% 374.67% -159.11% 74.60% -27.25% -22.42% 669.03%
Free Cash Flow Firm Q/Q Growth		 83.04% -454.25% 5.53% -27.02% 920.26% 238.22% -352.44% 3,325.60% -36.91% -24.00% 362.67%
Invested Capital Q/Q Growth		 41.30% -110.90% -90.55% 85.95% -28.83% -2,988.57% 525.80% -83.82% -19.67% 29.10% -365.24%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 0.00% 100.00% 100.00% 100.00% 100.00% 47.08% 47.74% 51.88% 45.18% 41.38% 50.15%
EBITDA Margin		 0.00% -91.20% -43.46% -5.35% 3.09% -3.54% 3.95% 4.50% -5.61% -10.85% 11.00%
Operating Margin		 0.00% -92.26% -44.18% -6.69% 1.00% -5.98% 0.89% 1.24% -9.76% -14.67% 8.00%
EBIT Margin		 0.00% -92.60% -44.55% -7.13% 0.85% -6.11% 1.06% 1.19% -9.78% -14.57% 8.12%
Profit (Net Income) Margin		 0.00% -93.41% -44.67% -7.29% 0.47% -6.52% 0.88% 1.12% -9.90% -14.51% 8.26%
Tax Burden Percent		 0.00% 100.88% 100.28% 102.29% 55.41% 106.62% 82.84% 94.00% 101.29% 99.56% 101.62%
Interest Burden Percent		 0.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 44.59% 0.00% 17.16% 6.00% 0.00% 0.00% -1.62%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.32% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 40.65% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -33.69% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -251.79% -2,157.99% -732.51% 11.42% -57.05% 5.78% 6.63% -77.70% -532.46% 503.05%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -207.25% 227.74% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 0.00% -116.18% -99.58% -17.94% 2.39% -12.26% 1.81% 1.85% -15.12% -24.18% 15.82%
Return on Assets (ROA)		 0.00% -117.21% -99.85% -18.35% 1.32% -13.07% 1.50% 1.74% -15.31% -24.08% 16.08%
Return on Common Equity (ROCE)		 0.00% -251.79% -2,157.99% -732.51% 11.42% -57.05% 5.78% 6.63% -77.70% -532.46% 503.05%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -4,388.88% -1,721.00% 0.00% 5.72% -41.05% 4.87% 6.02% -115.08% 382.34% 124.63%
Net Operating Profit after Tax (NOPAT)		 0.00 -7.22 -4.77 -0.95 0.15 -1.34 0.30 0.57 -3.68 -5.15 4.63
NOPAT Margin		 0.00% -64.58% -30.93% -4.68% 0.55% -4.19% 0.74% 1.16% -6.83% -10.27% 8.13%
Net Nonoperating Expense Percent (NNEP)		 0.00% -52.62% -68.53% -29.74% -1.30% -12.94% 0.90% -0.33% -17.32% -33.40% 1.20%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - - - 270.58% 122.66%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 52.92% 52.26% 48.12% 54.82% 58.62% 49.85%
SG&A Expenses to Revenue		 0.00% 46.26% 32.20% 20.11% 17.28% 20.59% 15.87% 18.56% 19.01% 22.07% 16.40%
R&D to Revenue		 0.00% 37.51% 27.86% 21.74% 17.73% 18.22% 17.53% 19.09% 21.43% 19.03% 11.99%
Operating Expenses to Revenue		 0.00% 192.26% 144.18% 106.69% 99.00% 53.06% 46.85% 50.64% 54.94% 56.05% 42.15%
Earnings before Interest and Taxes (EBIT)		 0.00 -10 -6.87 -1.44 0.23 -1.96 0.44 0.58 -5.27 -7.31 4.63
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 0.21 -10 -6.70 -1.08 0.84 -1.14 1.62 2.21 -3.02 -5.44 6.27
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 12.91 140.77 72.73 15,896.96 47.13 18.00 19.34 11.42 14.39 0.00 26.21
Price to Tangible Book Value (P/TBV)		 14.08 0.00 0.00 0.00 67.22 19.26 20.26 11.85 15.51 0.00 28.76
Price to Revenue (P/Rev)		 0.00 3.00 1.89 2.36 3.90 2.86 3.50 2.11 1.24 1.31 1.74
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 823.96 0.00 396.90 189.51 0.00 0.00 21.03
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.12% 0.00% 0.25% 0.53% 0.00% 0.00% 4.76%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 50.71 1,065.68 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 0.00 2.77 1.67 2.36 3.78 2.60 3.39 1.93 1.05 1.26 1.56
Enterprise Value to EBITDA (EV/EBITDA)		 442.38 0.00 0.00 0.00 122.16 0.00 85.74 42.92 0.00 0.00 14.22
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 442.62 0.00 318.05 162.69 0.00 0.00 19.26
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 683.41 0.00 458.43 166.23 0.00 0.00 19.25
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 54.91 28.72 0.00 14.60 14.25 0.00 12.06
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 99.40 91.15 0.00 29.43 29.91 0.00 14.56
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 14.33 0.01 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 5.67 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.38 -1.48 -9.69 -8.81 -1.49 -1.58 -1.04 -0.83 -1.39 -4.66 -6.64
Leverage Ratio		 1.86 2.15 21.61 39.92 8.63 4.36 3.86 3.81 5.07 22.12 31.29
Compound Leverage Factor		 0.00 2.15 21.61 39.92 8.63 4.36 3.86 3.81 5.07 22.12 31.29
Debt to Total Capital		 0.00% 0.00% 0.00% 93.48% 0.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 56.52% 0.71% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 36.96% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 6.52% 99.29% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 -0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 -0.04 -3.85 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 -0.05 0.11 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 -0.05 -21.53 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 -0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 10.30 -15.69 -10.97 -7.17 0.68 -0.09 2.20 1.04 -0.82 -2.49 0.80
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.84 0.82 0.79 0.68 0.99 1.10 1.13 1.13 0.90 0.63 0.94
Quick Ratio		 2.74 0.73 0.75 0.53 0.95 1.07 1.04 1.06 0.83 0.56 0.88
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -1.40 -6.19 -4.22 -3.89 1.03 0.92 -5.68 3.22 1.89 -6.11 6.12
Operating Cash Flow to CapEx		 -8,447.37% -1,990.06% -370.76% -100.00% 223.26% 130.86% -51.23% 272.53% 138.30% -734.09% 1,898.71%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 1.25 2.24 2.52 2.80 2.01 1.70 1.56 1.55 1.66 1.95
Accounts Receivable Turnover		 0.00 9.43 8.60 6.54 6.53 7.02 6.98 5.95 6.15 5.72 5.49
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 20.90 16.81 12.27 11.69 9.83 0.00 0.00 7.52 7.77 11.28
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 5.72 8.52 9.93 7.20 5.28 5.65
Days Sales Outstanding (DSO)		 0.00 38.71 42.47 55.82 55.92 51.97 52.28 61.31 59.37 63.81 66.53
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 63.84 42.84 36.77 50.69 69.11 64.59
Cash Conversion Cycle (CCC)		 0.00 38.71 42.47 55.82 55.92 -11.88 9.44 24.54 8.68 -5.30 1.94
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -1.46 -2.50 -3.05 -0.10 -0.98 -3.24 2.74 0.09 -5.48 -4.52 -6.01
Invested Capital Turnover		 0.00 -5.65 -5.56 -12.86 -49.80 -15.20 -163.51 34.71 -19.98 -10.03 -10.81
Increase / (Decrease) in Invested Capital		 1.40 -1.04 -0.55 2.94 -0.88 -2.26 5.98 -2.65 -5.57 0.96 -1.49
Enterprise Value (EV)		 95 31 26 48 102 83 139 95 57 63 89
Market Capitalization		 104 34 29 48 105 92 144 104 67 66 99
Book Value per Share		 $0.08 $0.03 $0.04 $0.00 $0.19 $0.43 $0.55 $0.67 $0.34 ($0.14) $0.27
Tangible Book Value per Share		 $0.07 ($0.05) ($0.02) ($0.06) $0.14 $0.40 $0.53 $0.65 $0.32 ($0.16) $0.25
Total Capital		 8.06 0.24 0.40 0.05 2.25 5.10 7.43 9.10 4.64 -1.90 3.77
Total Debt		 0.00 0.00 0.00 0.04 0.02 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.02 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -9.36 -2.59 -3.30 0.04 -3.22 -8.34 -4.69 -9.01 -10 -2.62 -9.79
Capital Expenditures (CapEx)		 0.11 0.32 0.77 1.23 0.83 2.22 3.28 2.38 2.87 0.84 0.39
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -2.39 -3.55 -4.87 -2.37 -3.32 -7.15 -3.26 -6.82 -12 -11 -11
Debt-free Net Working Capital (DFNWC)		 6.97 -0.97 -1.58 -2.37 -0.09 1.19 1.43 2.19 -2.28 -7.90 -1.48
Net Working Capital (NWC)		 6.97 -0.97 -1.58 -2.39 -0.10 1.19 1.43 2.19 -2.28 -7.90 -1.48
Net Nonoperating Expense (NNE)		 0.00 3.22 2.12 0.53 0.02 0.75 -0.06 0.02 1.66 2.13 -0.07
Net Nonoperating Obligations (NNO)		 -9.52 -2.74 -3.45 -0.11 -3.22 -8.34 -4.69 -9.01 -10 -2.62 -9.79
Total Depreciation and Amortization (D&A)		 0.21 0.16 0.17 0.36 0.61 0.83 1.18 1.63 2.25 1.87 1.64
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% -31.76% -31.62% -11.69% -12.28% -22.26% -7.93% -13.89% -23.01% -20.98% -19.79%
Debt-free Net Working Capital to Revenue		 0.00% -8.64% -10.24% -11.69% -0.32% 3.71% 3.49% 4.45% -4.23% -15.76% -2.61%
Net Working Capital to Revenue		 0.00% -8.64% -10.24% -11.82% -0.38% 3.71% 3.49% 4.45% -4.23% -15.76% -2.61%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.18) ($1.20) ($0.64) ($0.13) $0.01 ($0.17) $0.03 $0.04 ($0.39) ($0.54) $0.34
Adjusted Weighted Average Basic Shares Outstanding		 104.43M 8.70M 10.98M 11.03M 11.34M 11.84M 13.14M 13.20M 13.54M 13.55M 13.66M
Adjusted Diluted Earnings per Share		 ($0.18) ($1.20) ($0.64) ($0.13) $0.01 ($0.17) $0.02 $0.04 ($0.39) ($0.54) $0.33
Adjusted Weighted Average Diluted Shares Outstanding		 104.43M 8.70M 10.98M 11.03M 14.10M 11.84M 14.57M 14.16M 13.54M 13.55M 14.27M
Adjusted Basic & Diluted Earnings per Share		 ($0.18) ($1.20) ($0.64) ($0.13) $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 71.82M 11.24M 10.68M 10.99M 11.62M 12.73T 13.42M 13.52M 13.46M 13.59M 13.78M
Normalized Net Operating Profit after Tax (NOPAT)		 0.00 -7.22 -4.77 -0.95 0.15 -1.11 0.30 0.57 -3.11 -4.84 3.39
Normalized NOPAT Margin		 0.00% -64.58% -30.93% -4.68% 0.55% -3.46% 0.74% 1.16% -5.78% -9.66% 5.96%
Pre Tax Income Margin		 0.00% -92.60% -44.55% -7.13% 0.85% -6.11% 1.06% 1.19% -9.78% -14.57% 8.12%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -1.39% -8.71% 0.00%

Quarterly Metrics And Ratios for Champions Oncology

This table displays calculated financial ratios and metrics derived from Champions Oncology's official financial filings.

Metric Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026 Q3 2026
Period end date 7/31/2023 10/31/2023 1/31/2024 4/30/2024 7/31/2024 10/31/2024 1/31/2025 4/30/2025 7/31/2025 10/31/2025 1/31/2026
DEI Shares Outstanding		 13,459,539.00 13,479,215.00 13,593,767.00 13,593,767.00 13,593,766.00 13,593,767.00 13,819,236.00 13,826,904.00 13,777,170.00 13,788,421.00 13,886,326.00
DEI Adjusted Shares Outstanding		 13,459,539.00 13,479,215.00 13,593,767.00 13,593,767.00 13,593,766.00 13,593,767.00 13,819,236.00 13,826,904.00 13,777,170.00 13,788,421.00 13,886,326.00
DEI Earnings Per Adjusted Shares Outstanding		 -0.19 -0.15 -0.19 -0.01 0.10 0.05 0.33 -0.13 -0.03 0.02 -0.02
Growth Metrics		 - - - - - - - - - - -
Profitability Metrics		 - - - - - - - - - - -
Net Operating Profit after Tax (NOPAT)		 -1.79 -1.37 -1.80 -0.19 1.31 0.72 4.48 -1.40 -0.37 0.17 -0.19
Return On Investment Capital (ROIC_SIMPLE)		 - -1,471.51% 87.65% 10.01% -394.00% 105.89% 81.84% -37.25% -10.43% 4.06% -4.41%
Earnings before Interest and Taxes (EBIT)		 -2.54 -2.06 -2.52 -0.19 1.33 0.74 4.52 -1.97 -0.45 0.26 -0.24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -2.09 -1.58 -2.04 0.27 1.78 1.14 4.92 -1.57 -0.09 0.61 0.10
Valuation Ratios		 - - - - - - - - - - -
Leverage & Solvency		 - - - - - - - - - - -
Liquidity Ratios		 - - - - - - - - - - -
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 2.25 2.40 -0.01 -1.15 1.57 -2.63 -4.17 0.09 3.19 2.38 4.82
Efficiency Ratios		 - - - - - - - - - - -
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -2.97 -5.42 -6.38 -4.52 -3.22 -2.07 2.27 -6.01 -6.79 -4.29 -2.75
Increase / (Decrease) in Invested Capital		 -4.03 -3.77 -1.80 0.96 -0.26 3.35 8.64 -1.49 -3.56 -2.21 -5.02
Book Value per Share		 $0.14 $0.01 ($0.15) ($0.14) ($0.02) $0.05 $0.40 $0.27 $0.25 $0.30 $0.31
Tangible Book Value per Share		 $0.12 ($0.02) ($0.18) ($0.16) ($0.05) $0.03 $0.37 $0.25 $0.23 $0.28 $0.28
Total Capital		 1.90 0.09 -2.06 -1.90 -0.33 0.68 5.47 3.77 3.54 4.23 4.38
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -4.87 -5.51 -4.47 -2.62 -2.89 -2.75 -3.20 -9.79 -10 -8.52 -7.13
Capital Expenditures (CapEx)		 0.67 0.08 0.09 -0.00 0.00 0.09 0.04 0.25 0.05 0.24 0.04
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -10 -12 -13 -11 -8.88 -7.53 -3.38 -11 -12 -9.33 -7.62
Debt-free Net Working Capital (DFNWC)		 -5.46 -6.93 -8.77 -7.90 -5.99 -4.78 -0.17 -1.48 -1.68 -0.81 -0.49
Net Working Capital (NWC)		 -5.46 -6.93 -8.77 -7.90 -5.99 -4.78 -0.17 -1.48 -1.68 -0.81 -0.49
Net Nonoperating Expense (NNE)		 0.78 0.70 0.73 -0.08 -0.00 -0.01 -0.02 0.43 0.10 -0.07 0.09
Net Nonoperating Obligations (NNO)		 -4.87 -5.51 -4.32 -2.62 -2.89 -2.75 -3.20 -9.79 -10 -8.52 -7.13
Total Depreciation and Amortization (D&A)		 0.45 0.48 0.48 0.46 0.45 0.40 0.40 0.39 0.36 0.36 0.34
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.19) ($0.15) ($0.19) ($0.01) $0.10 $0.05 $0.33 ($0.14) ($0.03) $0.02 ($0.02)
Adjusted Weighted Average Basic Shares Outstanding		 13.51M 13.50M 13.59M 13.55M 13.59M 13.59M 13.70M 13.66M 13.79M 13.79M 13.89M
Adjusted Diluted Earnings per Share		 ($0.19) ($0.15) ($0.19) ($0.01) $0.09 $0.05 $0.31 ($0.12) ($0.03) $0.02 ($0.02)
Adjusted Weighted Average Diluted Shares Outstanding		 13.51M 13.50M 13.59M 13.55M 14.04M 14.02M 14.36M 14.27M 13.79M 14.46M 13.89M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 13.48M 13.59M 13.59M 13.59M 13.59M 13.82M 13.83M 13.78M 13.79M 13.89M 13.89M
Normalized Net Operating Profit after Tax (NOPAT)		 -1.79 -1.37 -1.80 -0.19 1.31 0.72 4.48 -1.40 -0.35 0.17 -0.13
Debt Service Ratios		 - - - - - - - - - - -
Payout Ratios		 - - - - - - - - - - -

Financials Breakdown Chart

Key Financial Trends

Champions Oncology’s latest quarter shows a meaningful turnaround in profitability and cash generation, but the balance sheet still carries notable leverage and working-capital pressure. For Q3 fiscal 2026, revenue rose year over year and the company moved back to near breakeven operating results after a loss in the prior quarter. However, cash declined sharply during the quarter, and current liabilities remain high relative to current assets.

  • Revenue improved year over year and sequentially. Q3 2026 revenue was $16.6 million, up from $15.0 million in Q2 2026 and $12.4 million in Q4 2025, showing a clear rebound in top-line momentum.
  • Margins improved sharply in the latest quarter. Gross profit was $7.7 million in Q3 2026, with gross margin holding near 46.6%, better than the roughly 42% level in Q4 2025.
  • Operating income nearly broke even. Q3 2026 operating loss narrowed to just $276,000, a big improvement from the $527,000 loss in Q2 2026 and the $2.0 million loss in Q4 2025.
  • Net loss narrowed to a small loss. The company reported a net loss of only $279,000 in Q3 2026, versus a $1.84 million loss in Q4 2025.
  • Adjusted cash flow improved versus the prior-year quarter. Champions Oncology generated $6.9 million of operating cash flow in Q4 2025 and $0.6 million in Q1 2026, showing that profitability and working capital can still swing materially quarter to quarter.
  • There is still a healthy deferred revenue base. Current deferred revenue was $10.0 million in Q3 2026, which can support future revenue recognition.
  • Accounts receivable remain a large part of current assets. AR was $12.1 million in Q3 2026, so collections will matter for liquidity and near-term cash flow.
  • Depreciation is manageable. Depreciation expense stayed in the mid-$300,000 range in recent quarters, so non-cash charges are not overwhelming reported earnings.
  • Cash fell sharply in Q3 2026. Cash and equivalents dropped to $7.1 million from $8.5 million in Q2 2026, and the company reported a $1.39 million net decrease in cash for the quarter.
  • Liquidity remains tight relative to obligations. Current liabilities of $20.7 million exceeded current assets of $20.2 million in Q3 2026, indicating a current ratio below 1.0.
  • Working capital continues to pressure operating cash flow. Q3 2026 operating cash flow was negative $1.34 million, driven in part by a $1.83 million drag from changes in operating assets and liabilities.
  • Balance sheet equity remains thin. Total common equity was only $4.3 million in Q3 2026, down from $5.5 million in Q3 2025, leaving limited cushion versus liabilities of $24.1 million.

Big picture: Champions Oncology appears to be moving in the right direction on revenue and operating performance, especially compared with the weak period in late fiscal 2025 and early fiscal 2026. The concern for investors is that the company is still operating with tight liquidity and a balance sheet that does not provide much margin for error. If revenue growth continues and working capital normalizes, earnings power could improve further; if not, cash burn and liabilities could remain a headwind.

07/19/26 07:08 PM ETAI Generated. May Contain Errors.

Champions Oncology Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Champions Oncology's fiscal year ends in April. Their fiscal year 2025 ended on April 30, 2025.

Champions Oncology's net income appears to be on a downward trend, with a most recent value of $4.70 million in 2025, rising from $0.00 in 2015. The previous period was -$7.28 million in 2024. See where experts think Champions Oncology is headed by visiting Champions Oncology's forecast page.

Champions Oncology's total operating income in 2025 was $4.55 million, based on the following breakdown:
  • Total Gross Profit: $28.56 million
  • Total Operating Expenses: $24.00 million

Over the last 10 years, Champions Oncology's total revenue changed from $0.00 in 2015 to $56.94 million in 2025, a change of 5,694,400,000.0%.

Champions Oncology's total liabilities were at $28.57 million at the end of 2025, a 1.9% increase from 2024, and a 616.4% increase since 2015.

In the past 10 years, Champions Oncology's cash and equivalents has ranged from $0.00 in 2018 to $10.12 million in 2023, and is currently $9.79 million as of their latest financial filing in 2025.

Over the last 10 years, Champions Oncology's book value per share changed from 0.08 in 2015 to 0.27 in 2025, a change of 252.0%.


Related Companies

Financial statements for NASDAQ:CSBR last updated on 7/16/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Hidden on Tesla's filing: A $12 billion "super startup"
Tesla's most recent SEC filing contains a single line showing $12 billion in revenue from a new venture Elon M...
Banyan Hill Publishing | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel